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Thestrikingclinical beneﬁts ofintermittentparathyroid hormoneinosteoporosishavebegun aneweraofskeletal anabolic agents.
One potential new agent is monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis.
1.Introduction
TheWntsignalingpathwaydemonstratesacomplexnetwork
of proteins well known for their roles in embryogenesis
but also involving normal physiologic processes of bone
formation in response to loading and unloading [1]. The
Wnt pathway involves a large network of proteins that
can regulate the production of Wnt signaling molecules
[2]. Several proteins that inhibit Wnt signaling [2]h a v e
been described. One such protein is sclerostin which binds
low-density lipoprotein receptor-related protein (LRP) and
inhibits Wnt signaling. This paper discusses both preclinical
and clinical data for sclerostin.
2. Sclerostin
Sclerostin which is a potent inhibitor of osteoblastogenesis
is a glycoprotein secreted by osteocytes. Sclerostin after
secretion by osteocytes travels through osteocyte canaliculi
to the bone surface where it binds to coreceptors LRP5 and
LRP6 thus preventing colocalization with frizzled protein
and Wnt signaling, and thereby reducing osteoblastogenesis
and bone formation [3].
Loss-of-function mutations in SOST are associated with
an autosomal-recessive disorder, sclerosteosis, which causes
progressive bone overgrowth [4]. A deletion downstream
of the SOST gene, which results in reduced sclerostin
expression, is associated with a milder form of the disease
called van Buchem disease [5]. Furthermore, SOST-null
mice have a high-bone-mass phenotype [6].
Sclerostin suppression is required for balanced remod-
eling in response to PTH [7]. Serum sclerostin levels are
signiﬁcantly higher in postmenopausal women than in
premenopausalwomenwithsigniﬁcantnegativecorrelations
between free estrogen levels and sclerostin as well as PTh and
sclerostin [8].
The development of a monoclonal antibody to sclerostin
that can be administered subcutaneously has allowed scien-
tists to evaluate the eﬀect of sclerostin blockade on bone
metabolism and bone mass. Li et al. [9]t r e a t e de s t r o g e n -
deﬁcient osteopenic rats with biweekly subcutaneous treat-
ment with 25mg/kg of a monoclonal antibody to sclerostin
for 5 weeks and restored trabecular bone mass to baseline
levels. Surface-based histomorphometry determined that the
increaseinbonemassresultedfromanincreaseinbonemass
at all skeletal envelopes, including cancellous, cortical bone
sites, and supervertebral sites. The increase in bone mass
and the change in microarchitecture were associated with
improved bone strength in both the appendicular and axial
skeleton. This data shows that pharmacologic inhibition of
sclerostin results in increased bone formation, bone mass,
and bone strength in rodents. In a mouse model of colitis,
short-term treatment with Scl Ab countered the eﬀects of
chronic inﬂammation on bone loss and resulted in increased
bone strength and bone formation [10]. Similarly, in rodent
models of fracture healing, Scl Ab treatment resulted in
increased callus density and bone strength at fracture sites
andacceleratedbonerepair[11].Thisincreasedboneforma-
tion and bone mass by sclerostin antibody was not blunted
in ovariectomized rats pretreated with alendronate [12].
Combinationofbothsclerostinantibodyandzoledronicacid2 Journal of Osteoporosis
resulted in additive eﬀects on bone parameters and bone
mass [13]. Treatment with sclerostin inhibitors is not gender
speciﬁc; treatment increases bone formation in male mice
[14].
Sclerostin inhibition in primates has recently been
reported by Ominsky [15]. A humanized sclerostin neu-
tralizing monoclonal antibody (Scl Ab) was administered
to gonad-intact female cynomolgus monkeys. Two once
monthly subcutaneous injections of Scl Ab were adminis-
tered at three dose levels (3, 10, and 30mg/kg) over two
months. Scl Ab resulted in dose-dependent increases in
bone formation on trabecular, periosteal, endocortical, and
intracortical surfaces. Bone density measurement showed
signiﬁcant increases (11–29% compared to vehicle alone)
at femoral neck and radial and tibial metaphysis. Addition-
ally signiﬁcant increases in trabecular thickness and bone
strength were seen in the lumbar vertebrae at the highest
dosestrength.Inanotherstudybythesameauthor,sclerostin
antibody stimulated bone formation and improved strength
of the fracture callus in a primate ﬁbular osteotomy model
[16]. Although these studies are short term, they suggest that
sclerostin inhibition resulting in increased bone formation
may be useful clinically in osteoporosis and fracture healing.
Despite the increases in anabolic activity, no increase in
bone resorption as measured by serum CTX was found in
the primate study, suggesting that coupling of resorption
and formation did not occur consistent with prior results
in sclerostin-knockout mice and in oophorectomized rats
treated with sclerostin antibody. This may suggest that the
mechanism of anabolic action diﬀers from PTH where bone
resorption markers are seen within one month of treatment.
This may represent direct activation of bone formation
(modeling) without activation of bone resorption (bone
remodeling).
In humans, antisclerostin antibody results in dose-
dependent increases in markers of bone formation in healthy
postmenopausal women [17].
The bone-forming eﬀects of the SOST antibody resem-
ble in many ways those of high-dose intermittent PTH
in rodents. Several studies have reported that sclerostin
gene expression and protein levels are reduced in animals
treated with daily injections of human parathyroid hormone
(hPTH) (1–34). Preclinical studies with a sclerostin inhibitor
appear to be somewhat diﬀerent from those with hPTH
(1–34). For example, all skeletal sites respond to anabolic
daily PTH treatment; the trabecular bone is most responsive,
followed by the endosteal surface and the periosteal surface.
In contrast, inhibition of sclerostin also results in signiﬁcant
bone formation at the periosteal surface. Also, studies ﬁnd
the increases in bone formation induced by antisclerostin
antibody, unlike PTH, not associated with increases in bone
resorption in the aged rodent skeleton.
Reduced mechanical stimulation leads to disuse osteo-
porosis, as seen in bedridden patients and in astronauts.
Lin et al. recently [18] reported that SOST-knockout mice
wereresistant to mechanicalunloading bone loss. Incontrast
to wild-type mice, Wnt/β-catenin signaling was not altered
by unloading in SOST-knockout mice. The data suggest a
potential major role for sclerostin in mediating the bone
response to unloading and propose it may be a promising
target for preventing disuse osteoporosis [18].
At this time, monoclonal antibody to sclerostin is being
considered for early phase 2 clinical trials in postmenopausal
women with osteoporosis and in fracture healing. The long-
term safety of sclerostin in humans has not been studied.
Additional clinical study data is needed to determine if the
rapid gain in bone mass is associated with bone of normal
strength and architecture and if boney overgrowth occurs
at areas such as the carpal tunnel resulting in carpal tunnel
syndrome, or around the lumbar spine neural foramen
resulting in lumbar radiculopathy or spinal stenosis [19].
In summary, treatments based on inhibition of sclerostin
may be a powerful way to restore skeletal bone strength in
our patients and may provide more eﬃcacious protection
fromhipfracturethancurrenttherapiesaswellaspotentially
improve fracture healing.
3. Conclusions
We now have a diverse menu of osteoporosis therapies
including both antiresorptive therapy and one anabolic
therapy (teriparatide). Current research suggests that in the
futurewemayhavemultiplediﬀerentanabolictherapiessuch
as sclerostin. The therapies may have orthopedic beneﬁts in
terms of fracture healing and fusions. The future of anabolic
therapies looks bright.
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